96 completed. 96 Phase 3, 4 Phase 2.
By phase and status
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Trials (filtered) newest first · largest first
All 96 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Panzyga, Placebo - Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | Phase 3 | Completed | 247 | 2020-10-05 | 2026-11-02 |
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
Obinutuzumab, Venetoclax, Fludarabine - Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Completed | 166 | 2020-05-28 | 2026-03-03 |
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 552 | 2019-09-17 | 2026-09-01 |
Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig
Hizentra - Secondary Immune Deficiency Disorder | Phase 2 / Phase 3 | Completed | 20 | 2018-11-05 | 2020-08-26 |
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Zanubrutinib, Ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Completed | 652 | 2018-11-01 | 2025-03-30 |
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
Obinutuzumab, Bendamustine, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 3 | Completed | 120 | 2018-08-10 | 2024-08-06 |
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 3 | Completed | 21 | 2018-03-28 | 2026-07-17 |
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Vitamin D, Rituximab, Placebo - Follicular Lymphoma, Small Lymphocytic Lymphoma | Phase 3 | Completed | 211 | 2017-09-07 | 2024-09-04 |
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
Fludarabine, Cyclophosphamide, Rituximab - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 926 | 2016-12-13 | 2024-12-30 |
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
Venetoclax - Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Completed | 210 | 2016-12-13 | 2023-02-22 |
A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Ibrutinib - Chronic Lymphocytic Leukemia | Phase 2 / Phase 3 | Completed | 11 | 2016-07-06 | 2020-02-27 |
A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)
Venetoclax - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 258 | 2016-06-22 | 2023-04-10 |
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Ublituximab, Ibrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 126 | 2015-01-27 | 2022-05-20 |
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Chlorambucil, Venetoclax, Obinutuzumab - Lymphocytic Leukemia, Chronic | Phase 3 | Completed | 445 | 2014-12-31 | 2025-11-06 |
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Ibrutinib, Obinutuzumab, Chlorambucil - Chronic Lymphocytic Leukemia, Small-Cell Lymphoma | Phase 3 | Completed | 229 | 2014-10-06 | 2020-09-21 |
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
tacrolimus, methotrexate, Mycophenolate mofetil - Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Completed | 101 | 2014-07-07 | 2023-09-11 |
Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression
Ibrutinib, Placebo - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 515 | 2014-04-30 | 2024-12-30 |
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Bendamustine, Venetoclax, Rituximab - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 389 | 2014-03-17 | 2023-10-17 |
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ibrutinib, Next-line ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Completed | 269 | 2013-12-03 | 2024-09-19 |
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
IPI-145, Ofatumumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Completed | 99 | 2013-12-01 | 2023-09-21 |
Showing 20 of 96. Sign in to see all of them.
Narrower conditions
Leukemia, Lymphocytic, Chronic, B-Cell (96) · Lymphoma, Follicular (31) · Lymphoma, Non-Hodgkin (31) · Lymphoma, B-Cell, Marginal Zone (29) · Lymphoma, Large B-Cell, Diffuse (29) · Lymphoma, Mantle-Cell (29) · Hodgkin Disease (28) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (27) · Lymphoma, Large-Cell, Immunoblastic (26) · Multiple Myeloma (26) · Leukemia (25) · Lymphoma (25) · Burkitt Lymphoma (24) · Leukemia, Myeloid, Acute (22) · Lymphoma, T-Cell, Cutaneous (22)
Broader conditions
Chronic Disease (96) · Disease Attributes (96) · Hematologic Diseases (96) · Hemic and Lymphatic Diseases (96) · Immune System Diseases (96) · Immunoproliferative Disorders (96) · Leukemia, Lymphoid (96) · Lymphatic Diseases (96) · Neoplasms by Histologic Type (96) · Pathologic Processes (96) · Pathological Conditions, Signs and Symptoms (96) · Lymphoproliferative Disorders (90) · Neoplasms (83) · Leukemia (71)
Interventions
Rituximab (25) · Cyclophosphamide (23) · fludarabine (14) · Bendamustine Hydrochloride (11) · fludarabine phosphate (11) · ibrutinib (11) · Chlorambucil (10) · obinutuzumab (9) · venetoclax (7) · Peripheral Blood Stem Cell Transplantation (5) · Vincristine (5) · ofatumumab (5) · Cyclosporine (4) · Doxorubicin (4) · Mycophenolic Acid (4)
Sponsors
Hoffmann-La Roche (10) · German CLL Study Group (9) · Fred Hutchinson Cancer Center (6) · Pharmacyclics LLC. (4) · AbbVie (3) · Memorial Sloan Kettering Cancer Center (3) · Alliance for Clinical Trials in Oncology (2) · Case Comprehensive Cancer Center (2) · Celgene (2) · Eastern Cooperative Oncology Group (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · French Innovative Leukemia Organisation (2) · Genzyme, a Sanofi Company (2) · Gilead Sciences (2) · Janssen Research & Development, LLC (2)
Countries
United States (64) · Germany (34) · France (29) · Italy (29) · Canada (25) · Spain (25) · United Kingdom (25) · Australia (22) · Austria (21) · Russia (21) · Belgium (20) · Poland (20) · Czechia (18) · New Zealand (18) · Israel (15)
Top investigators
Michael Hallek, MD (6) · Barbara Eichhorst, MD (2) · Brenda Sandmaier (2) · David J. Straus, MD (2) · John A. Glaspy, MD, MPH (2) · Adel Habib, MD (1) · Anita Szoke, MD (1) · Anna Fink, MD (1)
Results publications
PMID 38620092, PMID 40266025, PMID 28751558, PMID 31196847, PMID 33131249, PMID 24797299, PMID 24916506, PMID 29255066, PMID 29880603, PMID 32499241, PMID 32735048, PMID 34865212, PMID 35014928, PMID 35377947, PMID 35829925, PMID 36617990, PMID 15459300, PMID 16148284, PMID 16219797, PMID 16344317, PMID 16710026, PMID 17283363, PMID 17283364, PMID 17296974, PMID 17389338, PMID 17397698, PMID 17658394, PMID 17889355, PMID 18293016, PMID 19016733, PMID 19605849, PMID 19738118, PMID 20511662, PMID 20888994, PMID 21139079, PMID 21483000, PMID 21659360, PMID 21992852, PMID 22157574, PMID 22168274, PMID 22337714, PMID 22480131, PMID 23091097, PMID 23433739, PMID 23525797, PMID 24401022, PMID 24450857, PMID 24652989, PMID 24881631, PMID 25103870
NIH funding
2009 (4), 2005 (2), 2008 (2), 2015 (2), 2019 (2), 2023 (2), P01CA015396 (2), P30CA006973 (2), P30CA015704 (2), P30CA068485 (2), U10CA021115 (2), 2004 (1), 2014 (1), 2016 (1), 2018 (1)